A Docking Simulation Study of Some Herbal Molecules Against Influenza A Virus by Targeting Neuraminidase

Author(s): Rajesh K. Kesharwani*, Simran Kumari, Dev Bukhsh Singh, Sandeep Tripathi

Journal Name: Current Traditional Medicine

Volume 6 , Issue 2 , 2020

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Background: Human Swine flu is a viral disease caused by Influenza A virus, an orthomyxovirus, contains the glycoprotein neuraminidase described as H1N2. Neuraminidase, a glycoside hydrolase enzyme assist in budding from the host cells. The medicines available for the treatment of swine flu are Oseltamivir and Zanamivir acting against glycoproteins, mainly haemagglutinin and neuraminidase. Ayurvedic medicinal system described many herbs which acts as antiviral and among that Curcumin, Bisdemethoxycurcumin, Cyclocurcumin, Ascorbic Acid and Eugenol have been selected based on their potential antiviral properties.

Objective: This study aims to provide the interaction between Curcumin, Bisdemethoxycurcumin, Cyclocurcumin, Ascorbic Acid and Eugenol (herbal molecules) against influenza A virus by targeting Neuraminidase.

Methods: The selected protein target (1NN2.pdb) of swine flu (neuraminidase) was downloaded from Protein Data Bank with resolution 2.2 A0. The ligands (Curcumin, Cyclocurcumin, Bisdemethoxycurcumin, Ascorbic acid, Eugenol and Zanamvir) for the docking study have been download form PubChem database. The present study has been performed using docking simulation with the help of AutoDock Vina.

Results: Result shows that the Curcumin, Bisdemethoxycurcumin and Cyclocurcumin is showing good binding affinity with target protein, Nuraminidase as compared to known drug Zanamivir and other selected ligands (Eugenol, Ascorbic Acid). The docking energy values varies between -4.9 to -7.5 Kcal/mole.

Conclusion: The present study has shown that the Curcumin, Bisdemethoxycurcumin and Cyclocurcumin showing good binding affinity with target protein, Nuraminidase as compared to known binder Zanamivir and other selected ligands (Eugenol, Ascorbic Acid). Curcumin and their derivatives (Bisdemethoxycurcumin, Cyclocurcumin) based drugs may act singly or synergistically along with other known drugs and prove to be more effective for influenza type A treatment.

Keywords: Curcumin, tulsi, antiviral, influenza A, docking, nueramindase.

[1]
Aggarwal BB, Sundaram C, Malani N, Ichikawa H. Curcumin: the Indian solid gold. Adv Exp Med Biol 2007; 595: 1-75.
[http://dx.doi.org/10.1007/978-0-387-46401-5_1] [PMID: 17569205]
[2]
John D. One hundred useful raw drugs of the Kani tribes of Trivandrum forest division, Kerala, India. Int J Crude Drug Res 1984; 22(1): 17-39.
[http://dx.doi.org/10.3109/13880208409070646]
[3]
Mishra S, Karmodiya K, Surolia N, Surolia A. Synthesis and exploration of novel curcumin analogues as anti-malarial agents. Bioorg Med Chem 2008; 16(6): 2894-902.
[http://dx.doi.org/10.1016/j.bmc.2007.12.054] [PMID: 18194869]
[4]
Singh DB, Gupta MK, Kesharwani RK, Misra K. Comparative docking and ADMET study of some curcumin derivatives and herbal congeners targeting β-amyloid. Netw Model Anal Health Inform Bioinform 2013; 2(1): 13-27.
[http://dx.doi.org/10.1007/s13721-012-0021-7]
[5]
Akram M, Shahab-Uddin AA, Usmanghani K, Hannan A, Mohiuddin E, Asif M. Curcuma longa and curcumin: A review article. Rom J Biol Plant Biol 2010; 55(2): 65-70.
[6]
Kesharwani RK, Misra K. Prediction of binding site for curcuminoids at human topoisomerase II α protein; an in silico approach. Curr Sci 2011; 101(8): 1060-5.
[7]
Singh DV, Agarwal S, Kesharwani RK, Misra K. 3D QSAR and pharmacophore study of curcuminoids and curcumin analogs: Interaction with thioredoxin reductase. Interdiscip Sci 2013; 5(4): 286-95.
[http://dx.doi.org/10.1007/s12539-013-0177-6] [PMID: 24402822]
[8]
Anand P, Thomas SG, Kunnumakkara AB, et al. Biological activities of curcumin and its analogues (Congeners) made by man and Mother Nature. Biochem Pharmacol 2008; 76(11): 1590-611.
[http://dx.doi.org/10.1016/j.bcp.2008.08.008] [PMID: 18775680]
[9]
Singh P, Rizvi SI. Curcumin activates erythrocyte membrane acetyl chlolinesterase. Lett Drug Des Discov 2013; 10(6): 550-6.
[10]
Kim H, Jang M, Kim Y, et al. Red ginseng and vitamin C increase immune cell activity and decrease lung inflammation induced by influenza A virus/H1N1 infection. J Pharm Pharmacol 2016; 68(3): 406-20.
[http://dx.doi.org/10.1111/jphp.12529] [PMID: 26898166]
[11]
Ely JT. Ascorbic acid role in containment of the world avian flu pandemic. Exp Biol Med (Maywood) 2007; 232(7): 847-51.
[PMID: 17609500]
[12]
Pavithra B. Eugenol-a review. J Pharm Sci Res 2014; 6(3): 153-4.
[13]
Raja MR, Srinivasan V, Selvaraj S, Mahapatra SK. Versatile and synergistic potential of eugenol: A review. Pharm Anal Acta 2015; 6(5): 367.
[14]
Thosar N, Basak S, Bahadure RN, Rajurkar M. Antimicrobial efficacy of five essential oils against oral pathogens: An in vitro study. Eur J Dent 2013; 7(Suppl. 1): S71-7.
[http://dx.doi.org/10.4103/1305-7456.119078] [PMID: 24966732]
[15]
Ma M, Ma Y, Zhang GJ, et al. Eugenol alleviated breast precancerous lesions through HER2/PI3K-AKT pathway-induced cell apoptosis and S-phase arrest. Oncotarget 2017; 8(34): 56296-310.
[http://dx.doi.org/10.18632/oncotarget.17626] [PMID: 28915591]
[16]
Madsen U, Krogsgaard-Larsen P, Liljefors T. Textbook of Drug Design and Discovery. Washington, DC: Taylor & Francis 2002.
[17]
Reynolds CH, Merz KM, Ringe D, Eds. Drug Design: Structure- and Ligand-Based Approaches. 1st ed. Cambridge, UK: Cambridge University Press 2010.
[18]
Kesharwani RK, Singh DV, Misra K. Computation-based virtual screening for designing novel antimalarial drugs by targeting falcipain-III: A structure-based drug designing approach. Jour Vec Bor Dis 50(2): 93.
[19]
Kesharwani RK, Misra K, Singh DB. Perspectives and challenges of tropical medicinal herbs and modern drug discovery in the current scenario. Asian Pac J Trop Med 2019; 12(1): 1-7.
[20]
Avian influenza (“bird flu”) - Fact sheet WHO.
[21]
Transmission of Influenza Viruses from Animals to People. 2006.
[22]
Klenk HD,, Matrosovich M,, Stech J. Avian Influenza: Molecular Mechanisms of Pathogenesis and Host Range Animal Viruses: Molecular Biology 253. Caister Academic Press 2008.
[23]
Kawaoka Y, Ed. Influenza Virology: Current Topics. Caister Academic Press 2006.
[24]
Berman HM, Westbrook J, Feng Z, et al. The Protein Data Bank. Nucleic Acids Res 2000; 28(1): 235-42.www.rcsb.org
[http://dx.doi.org/10.1093/nar/28.1.235] [PMID: 10592235]
[25]
Trott O, Olson AJ. 2010; AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. Jour comp chem 31(2): 455-61.
[26]
Stiver G. The treatment of influenza with antiviral drugs. CMAJ 2003; 168(1): 49-56.
[PMID: 12515786]
[27]
Lao CD, Ruffin MT IV, Normolle D, et al. Dose escalation of a curcuminoid formulation. BMC Complement Altern Med 2006; 6: 10.
[http://dx.doi.org/10.1186/1472-6882-6-10] [PMID: 16545122]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 6
ISSUE: 2
Year: 2020
Page: [147 - 154]
Pages: 8
DOI: 10.2174/2215083805666190808092031
Price: $25

Article Metrics

PDF: 10
HTML: 4